Future Perspectives and Role of Vascular Endothelial Growth Factor Inhibitors in Oncology

Clinical Trials of anti-angiogenic drugs have reported their potential in inhibiting cancer. Clinical development has been amplified significantly over the last few years, seeking its positive impact on oncology. Presently, three direct inhibitors associated with Vascular Endothelial Growth Factor (VEGF) pathway are approved in cancer therapy. Other agents actively blocking the VEGF pathway are in progressive phases of clinical development and have revealed up-and-coming outcomes. With the advent of such innovations, some critical doubts and queries concerning the use of novel molecular-targeted agents have arisen. Primarily, the action mechanisms of VEGF inhibitors are yet not precise. The current study has reviewed the progress, futuristic perspectives, and role of VEGF inhibitors in oncology while emphasizing an explanation of the underlying mechanisms of action of Vascular Endothelial Growth factor inhibitors.